A new review found that GLP-1 weight-loss drugs significantly reduced the risk of heart attacks, strokes, and premature death. The treatment also lowered rates of non-fatal heart attacks, hospital admissions for heart failure, and deaths from any cause.
Chronic liver disease in the US costs $41.57 billion, with prescription medication expenditures accounting for nearly half of all-cause healthcare expenditures. Poor adherence to antiviral medications is a key factor in preventing disease progression and treatment, with high out-of-pocket costs increasing non-adherence risk.
Researchers from UH, Baylor College of Medicine and MD Anderson Cancer Center propose a new treatment approach for Crohn's disease by targeting the stress signal that fuels inflammation. They found that repurposing two existing cancer medications can promote natural repair and regeneration of the intestinal lining.
A new study shows that while dental opioid prescription fills in the US have dropped by 27% since 2021, the rate remains higher than in other developed countries and the US territory of Puerto Rico. The study suggests that some US dentists are still overprescribing opioids.
A recent study from the University of Eastern Finland found that people with Parkinson's disease are using psychotropics more frequently than controls, even before diagnosis. The use of psychotropic medications increases as the disease progresses, reflecting emerging non-motor symptoms and worsening disease progression.
A new analysis found that prescriptions for curable hepatitis C drugs have declined sharply in recent years, leaving millions without treatment. The researchers urge swift actions to deliver the drugs to those who need them, including increased screening and system-level changes.
A new study by University College London found that gabapentinoids, prescribed for chronic pain, double the risk of hospitalization for drug poisoning when combined with benzodiazepines or opioids. The risk persists even after starting gabapentinoid treatment, suggesting they may not be an effective solution to reduce poisoning risks.
A new Cochrane review of 17 clinical trials found that anti-amyloid Alzheimer's drugs have no significant impact on cognitive decline or dementia severity, but may increase the risk of brain swelling and bleeding. The evidence suggests that these drugs are unlikely to provide clear benefit to patients.
SourceCochrane·JournalCochrane Database of Systematic Reviews·TypeSystematic review·DateApr 15, 2026
Researchers identified patient-reported symptoms associated with GLP-1s, including menstrual changes, fatigue, and temperature-related complaints, that may not be fully captured in clinical trials or drug labeling. Nearly 4% of Reddit users reported reproductive symptoms, and fatigue was the second most common complaint.
Scientists at the University of Virginia Health System have developed a suite of AI-powered tools, called YuelDesign, YuelPocket and YuelBond, to transform how new drugs are created. These tools can design drug molecules tailored to fit their protein targets exactly, even accounting for protein flexibility.
A new analysis from UC San Francisco argues that diagnostics are being overlooked, slowing progress against major diseases despite advances in targeted therapies. The study suggests that nearly half of the world's population lacks adequate access to diagnostics due to inadequate investment and insurance reimbursement.
Researchers at the University of Waterloo have discovered a safer and more effective way to treat Alzheimer's disease by combining anti-amyloid antibodies with molecules found in grapes, berries, peanuts, and turmeric. This combination approach neutralizes amyloid protein clumping in the brain, leading to better outcomes.
A randomized trial found that duloxetine does not prevent painful neuropathy caused by oxaliplatin-based chemotherapy in patients with stage II or III colorectal cancer. The study suggests that duloxetine should only be used for managing existing neuropathy, not prevention.
The Alliance for Clinical Trials in Oncology is enrolling adolescent and young adult cancer patients in various trials, including genetic services and treatment studies. These trials aim to address longstanding gaps in care and improve outcomes for AYAs with cancer.
City St George's, University of London, is partnering with Paradigm Biopharmaceuticals to test a potential treatment for osteoarthritis. The partnership aims to investigate the mechanism of action of pentosan polysulfate sodium (iPPS) on bone marrow lesions, which are linked to pain in osteoarthritis.
In this randomized clinical trial, mirtazapine effectively reduced methamphetamine use in adults with methamphetamine use disorder. The study's findings have important implications for the treatment of this condition, which currently lacks approved pharmacotherapies.
Researchers identified NOX-1 as a key molecular target to prolong ketamine's therapeutic benefits. Combining ketamine with NOX-1 inhibitors significantly extended its antidepressant-like effects. K-4, a novel AMPAR modulator, also showed rapid antidepressant effects that persisted for at least 2 weeks.
Early-stage drug development has nearly doubled globally over the past decade, driven by a shift from a US-dominated system to a two-hub structure. This change may have implications for scientific workforce development, investment, and patient access to new therapies.
Researchers have identified and overcome metabolic instability as the key barrier to developing ovalicin, a potent relative of fumagillin. Using chem-bio hybrid synthesis, they created metabolically stable drug candidates that worked in animal models of amebiasis.
A Concordia-led study reveals that many Canadian surgery residents scored below the threshold of adequate pain knowledge, with limited grasp of the biopsychosocial model and unpreparedness to treat pain in children. This highlights the need for improved medical training to address this critical gap.
A study found that cancer patients during the last phase of life experienced more bleeding events than thromboembolic events. Most patients continued their antithrombotic therapy despite increased bleeding risk, with over 28% experiencing at least one bleeding episode.
The NRG-LU005 trial found that immunotherapy atezolizumab did not improve survival for patients with limited-stage small cell lung cancer when added to chemoradiation. Twice-daily radiation therapy, however, was associated with improved survival in this population.
Research reveals associations between antiseizure drugs and neurodevelopmental disorders in children, with valproate and zonisamide linked to increased risks. The study highlights the need for continued monitoring of new antiseizure drugs and further evaluation of their safety during pregnancy.
Research shows that bacteria harbor resistance genes may respond differently to antibiotics under non-standard conditions. This affects treatment efficacy and contributes to understanding antimicrobial resistance development and spread. Understanding these variations is crucial to combat global public health threats.
New prescriptions for stimulants among adults with ADHD more than doubled since the COVID-19 pandemic, with the largest increases among younger adults. The trend is driven by improved recognition and treatment of ADHD in adulthood, as well as increased access to care and virtual health services.
The Alliance for Clinical Trials in Oncology is spotlighting new trials for colorectal cancer in March, focusing on early detection methods and treatments for treatment delays and loss of appetite. The trials aim to improve patient outcomes, with several enrolling patients with newly diagnosed colon or rectal cancer.
A new medication called zorevunersen has been found to reduce seizures in children with Dravet syndrome by up to 91%, improving their quality of life and behavior. The study, led by University College London and Great Ormond Street Hospital, also showed the potential to reduce the impact of the condition on mental processes.
Researchers investigated low-dose lithium as a potential treatment for mild cognitive impairment in a pilot clinical trial. The study found that none of the primary outcomes met the significance threshold, but effect size estimates suggest potential benefits for future trials.
A study by São Paulo State University found that an iron-based compound eliminated lung infection in mice after 30 days of treatment. The researchers developed lipid nanoparticles to improve stability and duration of action, outperforming standard antibiotics in eliminating the bacterial load.
The study found that opioids provide only small, time-limited pain relief for certain pain conditions, such as stomach pain and dental surgery. Regular use of opioids comes with a risk of harm, including dependence and overdose.
A new study by Harvard T.H. Chan School of Public Health and the Department of Veterans Affairs Boston Healthcare System found that using GLP-1 receptor agonists in combination with adhering to healthy lifestyle habits significantly reduces cardiovascular risk among individuals with type 2 diabetes. The study showed that these two stra...
A study published in JAMA Network Open found that early hydrocortisone treatment increases the chance of surviving without lung disease for extremely premature babies. The treatment is safe and does not increase serious side effects.
Researchers are developing a new compound that can break down MDM2, a cancer-driving protein often found in triple-negative breast cancer, showing promise in shrinking tumors. The goal is to create an entirely new class of therapies for this aggressive and difficult-to-treat form of the disease.
Studies presented at the inaugural Multidisciplinary Radiopharmaceutical Therapy Symposium highlight the growing potential of RPTs to improve cancer outcomes. A meta-analysis shows Lu-177 PSMA-617 consistently prolongs progression-free survival without adding severe side effects for patients with advanced prostate cancer.
Researchers at the University of Iowa Health Care identified acetazolamide as a potential target for preventing opioid use disorder relapse. The study found that blocking the activity of brain enzyme carbonic anhydrase 4 boosted acid-sensing ion channels, reducing drug-seeking behavior and relapse in mice.
Researchers found that brexpiprazole significantly improved information processing speed without worsening psychiatric symptoms in patients with schizophrenia. Cognitive dysfunction is a persistent challenge, affecting daily functioning and social participation.
Researchers used Caenorhabditis elegans to model chemotherapy-induced neurological dysfunction and tested two compounds for improved recovery. Both sildenafil citrate and Resveramorph-3 significantly reduced seizure-like behaviors and duration, suggesting their potential as therapeutic candidates.
Researchers discovered that collaborative care programs improve quality of life, reduce costs, and alleviate caregiver burden for dementia patients. Adding lecanemab to treatment increased healthcare costs but was offset by the savings from collaborative care.
A new study found semaglutide to be an effective treatment for preventing secondary cardiovascular disease in US adults. The medication meets conventional thresholds when used alone, but its cost-effectiveness is improved with combination therapy.
A new study offers hope that kidney transplant patients may one day have a more effective treatment regimen. The Phase 2 pilot study showed improved kidney functioning in all patients who completed the study, with no patients experiencing rejection due to antibodies produced by the immune system.
A national clinical trial found that oxybutynin significantly reduced hot flash frequency and quality of life for men undergoing hormone therapy for prostate cancer. The study showed substantial improvements in hot flash symptoms, often within the first week of treatment.
The study found that metformin reduces the risk of developing Long COVID by approximately one case for every 50 cases of acute SARS-CoV-2 treated with 14 days of metformin. Metformin can be used alone or combined with other treatments to prevent Long COVID in most adults.
A new study led by Dr. Chu Chen suggests that combining THC with celecoxib may improve cognition and reduce Alzheimer's-related brain pathology in mice. The combination produced better outcomes than low-dose THC alone, including improved learning and memory performance and reduced markers of neuroinflammation.
The ISSCR is hosting a summit on access and affordability in cell and gene therapies to explore pricing, manufacturing, regulation, and reimbursement strategies. Experts will examine key barriers and emerging solutions across the access landscape.
The Japanese version of the rPATD questionnaire has been validated to assess attitudes towards medication reductions among older adults and their caregivers in Japan. The tool is reliable, valid, and easily understood, facilitating shared decision-making between healthcare providers and patients.
A national clinical trial found that abemaciclib, an oral cancer drug, may slow tumor growth in patients with aggressive meningiomas with specific genetic mutations. The trial showed promising results, with a median progression-free survival of 10 months and a median overall survival of 29 months.
Researchers analyzed medical records of 1,269 elderly patients with advanced cancer to find that over 70% were prescribed potentially inappropriate medications (PIMs), which declined closer to death. PIM discontinuation was more common among female patients, those with polypharmacy, and palliative care unit admissions.
A major U.S. clinical trial has uncovered a genetic factor that may inform how to optimize the dosing of abiraterone, a widely used hormone treatment for advanced prostate cancer. Researchers found that men who carry a specific version of the gene SULT2A1 clear abiraterone from their bodies more slowly, which could affect how well it w...
A new study by the University of Texas at Arlington examines how updated CDC guidelines can help nurse practitioners reduce opioid misuse and protect patients. The guidelines emphasize individualized care, clinical judgment, and ongoing reassessment to ensure safe prescribing practices.
Researchers have made a groundbreaking discovery about how bacteria swim upstream to cause infections, pointing to new designs for biomedical devices that can prevent contamination. The study found that wider channels with faster counterflows are more prone to invasion, but sharp corner designs can inhibit bacterial growth.
A new clinical trial, PAGODA, seeks to minimize treatment interruptions and help patients complete their chemotherapy as planned. The trial will test a structured plan to guide doctors in making small, proactive changes to chemotherapy doses to prevent treatment delays.
The FDA's regulation of mifepristone involves characterizing its decision-making process and rationale for key components. The agency's approach has evolved over time, with notable changes to its regulatory framework.
A new study found that 4.9 million adults in Great Britain have recently used a drug to support weight loss or were interested in using one in the near future. The usage far exceeds NHS England's initial goal of prescribing these drugs to 220,000 people over three years.
A new nanodrug called Nano-273 could offer improved survival for patients with pancreatic and lung cancers by activating the immune system and blocking tumor growth. The drug, developed by University of Houston researcher Wei Gao, has shown promising results in early studies.
Researchers at the University of Illinois discovered that propofol, a common anesthetic agent, can improve cognitive function after surgery in older individuals. Additionally, intranasal insulin was found to mitigate age-related memory impairment by modulating neuroinflammatory mechanisms.
Researchers at UVA Health System discover how traumatic brain injury increases Alzheimer's risk and find a potential prevention strategy using a hollowed-out virus to deliver repair supplies. The approach could help limit neurodegeneration and potentially prevent other neurological diseases.
Acute sepsis alters fluid kinetics and creates a 'third space' resistant to adrenergic modulation, leading to maldistribution of crystalloid fluid. Vasoactive drugs have limited effect on fluid distribution in septic sheep compared to healthy animals.
A team of researchers has identified two proteins critical to the destruction of red blood cells by the Oroya fever pathogen. This discovery paves the way for a potential novel therapy against this deadly neglected tropical disease.
Combocat integrates miniaturized drug dispensing with machine learning to efficiently uncover promising drug combinations. The platform's capabilities were published in Nature Communications, demonstrating its potential for scaling up drug combination screening.
Researchers at the University of Plymouth investigate why drugs used to treat other tumours are ineffective against NF2-related schwannoma and meningioma tumours. They explore repurposing clinically tested cancer drugs to target MDR mechanisms, which may lead to effective therapies for patients with these tumours.